Literature DB >> 26912650

RE: Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.

Boris Freidlin1, Edward L Korn1.   

Abstract

Mesh:

Substances:

Year:  2016        PMID: 26912650      PMCID: PMC5072374          DOI: 10.1093/jnci/djv430

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  1 in total

1.  Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.

Authors:  Denis L Jardim; Denis L Fontes Jardim; Maria Schwaederle; Caimiao Wei; J Jack Lee; David S Hong; Alexander M Eggermont; Richard L Schilsky; John Mendelsohn; Vladimir Lazar; Razelle Kurzrock
Journal:  J Natl Cancer Inst       Date:  2015-09-15       Impact factor: 13.506

  1 in total
  1 in total

1.  CAR-T cells forge ahead, Novartis reorganizes.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2016-11-08       Impact factor: 54.908

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.